Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC.

http://meetinglibrary.asco.org/content/110134?media=vm&poster=1

_________________________________________________________

Most importantly, read this sinapsis from Biomaven (VERY positive for Ariad's '113, imo):

http://meetinglibrary.asco.org/content/110134?media=vm&poster=1

Thanks for the PFE poster

Not much in the way of a dose response or difference between 2nd and 3rd line, which is all a bit strange. Also nothing much in the way of the dramatic responses which is what one might have expected based on the preclinical data.

All-in-all seems on the disappointing side (which of course is good for Ariad) but too bad for patients.